Competact (pioglitazone metformin): Reviews and patient testimonials
Back to the list of medications
Medication indications
Competact 15 mg/850 mg film-coated Tablets
Competact is indicated as second line treatment of type 2 diabetes mellitus adult patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.
After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.
Route of administration: Oral
Molecule: pioglitazone, metformin
Patients' opinions on Competact
Conditions related to this medication
Fact sheet
See the fact sheet
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.